Back to communiqués

Wegovy drug coverage

News Release

We wish to inform you that Wegovy1 will be covered as of November 15, 2024, in plans that include coverage of weight management drugs.

To promote optimal use of this drug while ensuring the long-term sustainability of group drug plans, reimbursement will be subject to prior authorization.

Weight management drug coverage

Preserving the physical and mental health of plan members through continued access to a comprehensive plan that meets their needs is an integral part of our PharmAssist drug management program.

That is why, for the health of these persons, we recommend that treatments for obesity and weight management be covered by drug plans, according to pre-established criteria.

As these treatments have an important preventive component, we believe that reducing excess weight can have significant, positive benefits for their health and, by the same token, for group insurance plan expenses.

If you have any questions, please contact your advisor or your iA Financial Group Account Executive.

PharmAssist is included in all our drug plans as part of our comprehensive offering of drug management solutions for our group insurance clients.

1 WEGOVY® (semaglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management.